Jin David reported grant involving 1,190 shares of Fortress Biotech, Inc. at $1.82 for $2.16k on Oct 1, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Financial Officer
Chief Financial Officer
Filed Oct 1, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$2,164.61Shares × reported price
Shares traded
1,190Common Stock, par value $0.001
Price per share
$1.82Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
1,652,761Direct
Trade date
Oct 1, 2026Grant
Filed
Oct 1, 2026, 4:30 PM ET0-day reporting delay
Accession
0001930732-26-000006Code A · Transaction 232963
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

FBIO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
FBIO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −1.1%1w ago 0%1d ago 0%
Returns since7d −23%30d −29%90d180d1y

Footnotes in full

F1: The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2: Total holdings include 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units.